Method to estimate the age of tissues and cell types based on epigenetic markers
US-2016222448-A1 · Aug 4, 2016 · US
Detection of 5-hydroxymethylcytosine by glycosylation
US9816986B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9816986-B2 |
| Application number | US-201715440408-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 23, 2017 |
| Priority date | Sep 26, 2008 |
| Publication date | Nov 14, 2017 |
| Grant date | Nov 14, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are methods and kits for detecting a modified cytosine.
First claim
Opening claim text (preview).
We claim: 1. A method for detecting 5-hydroxymethylcytosine in a mammalian nucleic acid, the method comprising: contacting a sample comprising said mammalian nucleic acid with an enzyme that utilizes a labeled glucose or a labeled glucose-derivative donor substrate to add a labeled glucose molecule or a labeled glucose-derivative to a 5-hydroxymethylcytosine nucleic acid residue to generate a labeled glucosylated-5-hydroxymethylcytosine, wherein the enzyme is a beta-glucosyltransferase and wherein the labeled glucose or the labeled glucose-derivative donor substrate comprises a uridine diphosphate glucose (UDPG); and treating the contacted sample with a TET enzyme or a catalytically active fragment thereof comprising SEQ ID NO: 1. 2. The method of claim 1 , wherein the labeled glucose or the labeled glucose-derivative donor substrate is radioactively labeled. 3. The method of claim 1 , wherein the beta-glucosyltransferase comprises an Asp-Ile-Arg-Leu sequence. 4. The method of claim 1 , wherein the beta-glucosyltransferase is encoded by a T4 bacteriophage. 5. The method of claim 1 , wherein the mammalian nucleic acid comprises mammalian DNA. 6. The method of claim 1 , further comprising conducting a nucleic acid sequencing. 7. The method of claim 1 , wherein the mammalian nucleic acid comprises a 5-methylcytosine. 8. The method of claim 7 , further comprising distinguishing a 5-hydroxymethylcytosine from the 5-methylcytosine.
Assignees
Inventors
Classifications
Methylation markers · CPC title
Screening for compounds of potential therapeutic value · CPC title
- G01N33/5308Primary
for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title
involving oxidoreductase · CPC title
Glycosylase · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9816986B2 cover?
- Provided herein are methods and kits for detecting a modified cytosine.
- Who is the assignee on this patent?
- The Children'S Medical Center Corp, The Us Secretary Department Of Health & Human Services, Children'S Medical Center Corp
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5308. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Nov 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).